AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu, Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign.

AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates.

Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

A two-alarm fire caused nearly $1 million in damage, injured two Montgomery County firefighters, and displaced at least six families in Gaithersburg on Tuesday, July 1, officials said. Fire crews ...

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited (CBOE CA:ONCO) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...